The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Shares of Moderna finished March 11 down by 93% from their peak in 2021. In addition to its COVID-19 vaccine, Moderna markets ...

Moderna (MRNA) announced that the Medicines ... the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of age and older. The approval is based ...

Feb 28 (Reuters) - Britain's health regulator said on Friday it has approved Moderna's (MRNA.O), opens new tab vaccine for respiratory syncytial virus in adults 60 years and older. The shot ...

Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna.

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine evaluation. A 2023–24 vaccine effectiveness analysis of immunocompetent adults ...

Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...

Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...